It was previously reported from this laboratory that antigen-specific, delayed footpadswelling and skin test reactivity to certain fungal antigens could be transferred in mice by using spleen cells of actively sensitized mice as well as with immunogenic ribonucleic acid (RNA) or its dialysate prepared from such spleen cells (5 through 7). Reported herein are the preparation and partial characterization of Lawrence-type dialyzable transfer factor prepared from spleen cells of mice actively sensitized with Coccidioides immitis vaccine, Candida albicans vaccine, or BCG. Reactivity in the mice was assayed by the skin test and footpad-swelling methods.
MATERIALS AND METHODS Mice. Female inbred CF1 mice, aged 10 to 14 weeks, were obtained from a commercial source (Carworth Farms, New City, N.Y.) and maintained on pelleted food (Purina Mouse Chow, Ralston-Purina Co., St. Louis, Mo.) and water ad lib.
Antigens. Coccidioides antigen consisted of a sonically treated arthrospore-and mycelial-phase culture of thiomerasol-inactivated C. immitis. The stock antigen as prepared was termed a 1:5 dilution (5). Candida antigen consisted of sonically treated, heat-killed C. albicans serotype A (5). BCG was obtained as a viable lyophilized suspension (BCG vaccine, Eli Lilly and Co., Indianapolis, Ind.) and was reconstituted just prior to use. A killed suspension of Mycobacterium tuberculosis H3,Ra was obtained as a desiccated preparation (Difco Laboratories, Detroit, Mich.). Antigens were prepared and diluted in 0.85% saline.
Sensitization procedures. Candida antigen, 1:2, and coccidioides antigen, 1:10, were injected intradermally in a course of four doses at weekly intervals. The sites of inoculation were depilated 24 h earlier with a lotion (Nair, Carter-Wallace, New York), and 0.025-ml volumes were injected with a 26-gauge needle and syringe. BCG was administered as a single 0.1-ml injection into a hind footpad.
Sensitivity testing. To assay sensitivity to antigens, the skin test was used in the earlier phase of this study and the footpad-swelling test in the later phase. For skin testing, antigen was injected in 0.025-ml portions into depilated sites on the back of mice, and the diameter of the zone of induration was measured with a millimeter rule at 48 h. Solutions of 1:4 candida, 1:5 coccidioides, and 1:500 H37Ra antigen dilutions were used. H37Ra was used to test for sensitivity produced by BCG vaccination. Footpadswelling tests were performed by injecting 0.025 ml of the above antigen dilutions into one or both hind feet of the mice. The thickness was measured before and 48 h after injection, with a skin thickness dial gauge reading in 0.01-mm increments (Oditest Odi OOT, H. C. Kroplin, Hessen, German Federated Republic). Data are presented in terms of the difference, in 0.01-mm increments, between the footpad thickness just before and 48 h after antigen injection. Negative figures indicate that the footpad thickness decreased after injection.
Transfer factor. Dialyzable transfer factor was prepared from spleen cells, according to the method described by Lawrence for use with human peripheral blood leukocytes (3). Spleens were collected 1 week after the course of coccidioides or candida sensitization or 6 weeks after BCG inoculation. The spleens were coarsely minced in tissue culture medium 199 (Flow Laboratories, Silver Spring, Md.) and expressed through a Ten Broeck glass tissue grinder. The cells were washed three times by centrifugation at 250 x g for 10 min at room temperature. The cells were suspended to a concentration of 5 x 108 cells/ml; a few crystals of deoxyribonuclease and 50 mg of magnesium sulfate per ml were added, 258 Groups of six mice were each given an intraperitoneal injection of a transfer factor: coccidioides, candida, or BCG. A fourth group of nine uninoculated mice was kept as control. Two days later, the mice in each group were injected with a different one of the three antigens in each hind footpad. The three antigens were distributed among the mice so that each antigen was injected into six footpads. The controls were similarly footpad tested with the three antigens. All footpad responses were measured 48 h later ( Table 2) .
Each of the three transfer factor preparations induced a significant delayed footpad-swelling response to the homologous antigen but not to either of the two heterologous antigens.
The data thus demonstrate that the transfer factor preparations tested produced delayed skin test and footpad-swelling responses, and that the reactivity produced by each is antigen specific.
Sensitization interval and route of inoculation. Six groups of three mice each were injected with candida transfer factor. The transfer factor was given to three of the groups intraperitoneally, in a dose of 0.1 ml, and to three (Table 3) .
Transfer factor given either intraperitoneally or directly into the footpad induced footpadswelling responses, and these responses were antigen specific. By both routes, however, transfer factor administration must precede antigen challenge in order for reactivity to become manifest. When antigen was given at the same time as transfer factor, no response to antigen developed; in contrast, an interval of 24 or 48 h between transfer factor and antigen injections resulted in antigen-specific reactivity.
Enzyme sensitivity of transfer factor. Portions of coccidioides transfer factor were treated with the enzymes RNase, Pronase, and trypsin. Additional samples were treated with either RNase followed by Pronase, or RNase followed by trypsin. Groups of 10 mice were given intraperitoneal injections of these enzyme-treated transfer factor preparations, and, in addition, one group was given untreated transfer factor. A final group of untreated normal mice was left as control. Two days later, all mice were skin tested with coccidioides antigen (Table 4) .
Transfer factor activity was susceptible to Pronase but resistant to RNase and trypsin.
A portion of BCG transfer factor was treated with snake venom phosphodiesterase. This preparation was administered intraperitoneally into a group of 10 mice. Another group of 10 mice was similarly injected with untreated BCG transfer factor, while a third group of eight uninoculated mice was left as control. Two days later, all mice were footpad tested with H:,7Ra (Table 5) .
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The activity of BCG transfer factor was found to be sensitive to phosphodiesterase. h Diameter of induration; mean (standard error) at 48 h.
Mean footpad swelling, c > f; P < 0.01. "RNase (final concentration of 40 ,g/ml) incubated with transfer factor at 370C overnight.
" Pronase (final concentration of 200 ,ug/ml) incubated with transfer factor at 370C overnight.
f Mean footpad swelling, c > f; P < 0.01. g RNase (final concentration of 40 ,ug/ml incubated with transfer factor at room temperature for 1 h and then with Pronase (200 ,ug/ml) at 37°C overnight.
h One milligram of trypsin per ml incubated with transfer factor overnight at 370C.
i RNase (40 mg/ml, final concentration) incubated with transfer factor for 1 h at room temperature followed by 1 mg of trypsin per ml at 370C overnight. Evidence has been presented from this laboratory (5) and by others (1) that such reactivities, which were produced actively by sensitization with antigen or passively by administration of immune spleen cells or immunogenic RNA, reflect cell-mediated immunity. Enzymatic studies described here show that the activity of the coccidioides-specific murine transfer factor preparation is sensitive to Pronase but is resistant to RNase and trypsin. In addition, the BCG-specific transfer factor is sensitive to snake venom phosphodiesterase. Also, deoxyribonuclease was used in the preparation of the transfer factor (3), so presumably the transfer activity is resistant to that enzyme also. This pattern of enzyme sensitivity corresponds to that reported for human transfer factor tested in humans (1, 2, 8).
Lawrence has described two types of assay procedures in humans for transfer factor assay: local and systemic (4). In the local procedure, the transfer factor is injected intradermally, and 24 h later the antigen is similarly injected directly into the transfer factor inoculation site. In the systemic procedure, the transfer factor is injected intradermally into one arm, and 24 h later antigen is injected intradermally into the opposite arm. In general, smaller amounts of transfer factor will suffice to produce local as compared with systemic sensitization. The data presented herein with the murine model indicate that local reactivity can be produced by injection of transfer factor into the footpads. It should be noted, however, that the same antigen was not also given into the opposite footpad or into the skin, so that the possibility that systemic sensitization also resulted was not explored.
Furthermore, human transfer factor is usually given either subcutaneously or intradermally. In the mouse system, transfer factor was active when administered intraperitoneally, suggesting that other routes of administration in humans might be worth evaluating.
Responses did not occur to antigen given into the footpad when transfer factor was given simultaneously, either by the intraperitoneal or footpad route. However, if antigen was given 24 h after transfer factor, the footpad response was positive. The events occurring during this obligatory interval between transfer factor and antigen administration are unknown. It is particularly noteworthy, however, that when antigen and transfer factor are given simultaneously, the specific response is absent and not merely delayed. Possibly, the antigen may simply have diffused away from the site of administration by the time reactivity is established. Alternatively, there may be some type of active inhibition ofresponsiveness by antigen given at that early stage of the interaction of transfer factor with its receptor cell population.
Both the dialysate of immunogenic RNA as well as its RNase breakdown products were previously shown to transfer delayed skin test and footpad-swelling reactivity to fungal antigens in mice (5 through 7). The availability of this model system for Lawrence-type transfer factor as described here now pernits the direct comparison of the biological and biochemical characteristics of these small-molecularweight, immunologically active materials. These studies are currently in progress.
